Käsmann, L.* ; Taugner, J.* ; Eze, C.* ; Nieto, A.* ; Pelikan, C. ; Floersch, B.* ; Kenndoff, S.* ; Hofer, T.P. ; Nößner, E. ; Schulz, C.* ; Unterrainer, M.* ; Tufman, A.* ; Klauschen, F.* ; Jung, A.* ; Neumann, J.* ; Kumbrink, J.* ; Reinmuth, N.* ; Bartenstein, P.* ; Belka, C.* ; Manapov, F.*
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by consolidation therapy with durvalumab (PRECISION): Protocol for a prospective longitudinal biomarker study.
Transl. Lung Cancer Res. 11, 1503-1509 (2022)